Results 51 to 60 of about 1,019 (188)

Targeting IL-36 in Inflammatory Skin Diseases [PDF]

, 2023
Interleukin (IL)-36 cytokines are members of the IL-1 superfamily of cytokines. IL-36 cytokines are composed of three agonists (IL-36α, IL-36β, and IL-36γ) and two antagonists (IL-36 receptor antagonist [IL36Ra] and IL-38).
Akiyama, Masashi, Fukaura, Ryo
core   +1 more source

Pustular psoriasis as an autoinflammatory keratinization disease (AiKD): Genetic predisposing factors and promising therapeutic targets [PDF]

, 2022
Pustular psoriasis is a chronic inflammatory skin disease characterized by erythematous plaques with sterile pustules. It includes the distinct clinical entities generalized pustular psoriasis (GPP), acrodermatitis continua of Hallopeau (ACH) and ...
Akiyama, Masashi
core   +1 more source

Spesolimab Rapidly Resolved Capillary Leak Syndrome Associated with Generalized Pustular Psoriasis

Acta Dermato-Venereologica
Yoshiki Okada, Masahiro Kamata, Kotaro Hayashi, Kazumitsu Sugiura, Yayoi Tada   +4 more
doaj   +2 more sources

IL-1 Family Cytokines in Inflammatory Dermatoses : Pathogenetic Role and Potential Therapeutic Implications [PDF]

, 2022
The interleukin-1 (IL-1) family is involved in the correct functioning and regulation of the innate immune system, linking innate and adaptative immune responses.
Iznardo, Helena, Puig Sanz, Lluís, Universitat Autònoma de Barcelona   +2 more
core   +1 more source

Successful Control of Refractory Hidradenitis Suppurativa with Spesolimab: A Case Report [PDF]

Acta Dermato-Venereologica
Yangfan Lai, Yanzhuo Hu, Xiaoyao Fan, Baishuang Yue, Ying Ma   +4 more
doaj   +2 more sources

Spesolimab in patients with flare of generalized pustular psoriasis: A multicentre case-series [PDF]

, 2023
Dear Editor,Generalized pustular psoriasis (GPP) is a rare, potentially life-threatening, chronic inf lammatory disease character-ized by acute f lares of pustular eruptions that can be accom-panied by systemic inf lammation.
Bellinato, F, Costanzo, A, Dattola, A, De Simone, C, Girolomoni, G, Gisondi, P, Marzano, A V, Nacca, M, Pellacani, G, Pezzolo, E, Richetta, A G, Valenti, M, Zussino, M   +12 more
core   +1 more source

Spesolimab: First Approval

Drugs, 2022
Spesolimab (spesolimab-sbzo; SPEVIGO®) is an interleukin (IL)-36 receptor antagonist being developed by Boehringer Ingelheim for the treatment of various immune-mediated disorders. In September 2022, spesolimab was approved in the USA for the treatment of generalized pustular psoriasis (GPP) flares in adults.
openaire   +2 more sources

Generalized Pustular Psoriasis : A Review on Clinical Characteristics, Diagnosis, and Treatment [PDF]

, 2023
Generalized pustular psoriasis (GPP) is a rare, chronic, and severe inflammatory skin disorder characterized by sudden eruption of sterile pustules, often accompanied by systemic inflammation.
Carrascosa, José Manuel, Daudén, Esteban, de la Cueva, Pablo, Puig Sanz, Lluís, Rivera, Raquel, Universitat Autònoma de Barcelona   +5 more
core   +1 more source

Generalized Pustular Psoriasis with Breast Cancer Successfully Treated with Spesolimab Causing Neutrophilia: A Case Report [PDF]

Acta Dermato-Venereologica
Rina Obata, Mika Yamanaka-Takaichi, Hisayoshi Imanishi, Tomoko Oshimo, Daisuke Tsuruta   +4 more
doaj   +2 more sources

33356 A multinational chart review to examine gastrointestinal symptoms and their management in patients treated with apremilast for plaque psoriasis [PDF]

, 2022
Background: Diarrhea and nausea are the most common adverse events observed in phase 3 clinical trials and real-world studies of apremilast, an oral phosphodiesterase-4 inhibitor indicated for moderate-to-severe plaque psoriasis. Methods: A retrospective
Bouloc, Anne, Chang, Rose, Cheng, Wendy Y, Jullien, Denis, Klyachkin, Yuri, Nazareth, Tara, Nguyen, Catherine, Stein Gold, Linda F, Tuttle, Edward, Yu, Louise H   +9 more
core   +1 more source